The World Health Organization has established a goal of eliminating viral hepatitis (hepatitis B and hepatitis C) by the year 2030.

In support of this target, Gilead’s Medical Affairs team has created the CHIME Program (Conquering Hepatitis via Micro-Elimination), offering research grant funding for up to 30 hepatitis C virus (HCV) projects which focus on breaking down national and international HCV elimination goals into micro-elimination projects among smaller and more defined populations.

Gilead will support projects with research grants of up to $350,000 each, with an emphasis on achieving geographic distribution across the globe. Successful proposals will demonstrate clear scientific objectives, defined timelines, a comprehensive operational plan and the potential to generate data that has relevance to the medical community and policy makers.

Key Dates & Program Specifics:

  • Gilead will evaluate and award submissions on a rolling basis beginning next month. Proposals will be initiated with a Letter of Intent (LOI), submitted to:
  • A LOI should be submitted using the template provided in the sidebar. Proposals should not exceed 1,000 words.
    • 30 April 2018: LOI submission window opens
    • 20 September 2018: LOI submission window closes

    LOI applicants should use the downloadable LOI and Overhead Policy Forms available in the sidebar.

Questions about the program or application process should be submitted to your local Gilead Medical Scientist or to

At Gilead we are inspired by the opportunity to address unmet medical needs for patients living with life-threatening diseases around the world.

Downloadable Documents